- Home
- MNOV vs FLL Comparison
MNOV vs FLL Comparison
Compare MNOV & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | FLL |
|---|---|---|
| Founded | 2000 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.4M | 77.7M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MNOV | FLL |
|---|---|---|
| Price | $1.79 | $2.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $7.50 | $4.00 |
| AVG Volume (30 Days) | 46.9K | ★ 114.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.45 |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $302,376,000.00 |
| Revenue This Year | N/A | $7.54 |
| Revenue Next Year | $180.00 | $6.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | 3.53 |
| 52 Week Low | $1.17 | $1.96 |
| 52 Week High | $1.96 | $3.61 |
Technical Indicators
Market Signals| Indicator | MNOV | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 77.94 | 44.37 |
| Support Level | $1.28 | $1.98 |
| Resistance Level | $1.80 | $2.74 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 87.00 | 30.56 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.